BIBF 1120 esylate
Cat. No.: DC8608
Featured
Chemical Structure
656247-18-6
We are official vendor of:
More than 5000 active chemicals with high quality for research!
Field of application
Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM.
Cas No.: |
656247-18-6 |
Chemical Name: |
(Z)-methyl3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate |
Synonyms: |
Nintedanib; BIBF1120; Vargatef; BIBF-1120 |
SMILES: |
N1C2=C(C=CC(C(OC)=O)=C2)/C(=C(/NC2=CC=C(N(C)C(CN3CCN(C)CC3)=O)C=C2)\C2=CC=CC=C2)/C1=O.C(S(O)(=O)=O)C |
Formula: |
C33H39N5O7S |
M.Wt: |
649.76 |
Sotrage: |
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: |
Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively. |
In Vivo: |
Nintedanib (BIBF 1120) (25-100 mg/kg daily p.o.) is highly active in all tumor models, including human tumor xenografts growing in nude mice and a syngeneic rat tumor model. This is evident in the magnetic resonance imaging of tumor perfusion after 3 days, reducing vessel density and vessel integrity after 5 days, and profound growth inhibition[1]. Nintedanib (BIBF 1120) is orally available and displays encouraging efficacy in in vivo tumor models while being well tolerated[2]. |
In Vitro: |
Nintedanib (BIBF 1120) binds to the ATP-binding site in the cleft between the amino and carboxy terminal lobes of the kinase domain. Nintedanib (BIBF 1120) inhibits proliferation of PDGF-BB stimulated BRPs with EC50 of 79 nM in cell assays. Nintedanib (BIBF 1120) (100 nM) blocks activation of MAPK after stimulation with 5% serum plus PDGF-BB. Nintedanib (BIBF 1120) prevents PDGF-BB stimulated proliferation with an EC50 of 69 nM in cultures of human vascular smooth muscle cells (HUASMC)[1]. |
MSDS
COA
LOT NO. |
DOWNLOAD |
|
|
2018-0101 |
|
2018-0101 |
|
Get Quote